EndoStim is a medical device company founded in 2009 focused on treating Gastro-esophageal Reflux Disease (GERD), commonly known as acid reflux, through electrical stimulation. Acid reflux is a condition affecting millions of people worldwide and despite treatment with medications such as proton pump inhibitors (PPIs), many patients suffer continued symptoms such as regurgitation and nighttime reflux. EndoStim’s innovative technology addresses one of the primary causes of acid reflux — namely a weak or dysfunctional lower esophageal sphincter (LES) that allows for reflux of stomach contents into the esophagus.
Our mission is to develop and commercialize a revolutionary treatment for severe gastroesophageal reflux disease by normalizing physiological function of the esophagus through electrical stimulation.
EndoStim is headquartered in St. Louis, Missouri, USA and The Hague, The Netherlands, and distributes its products throughout Europe, Asia, and Latin America. The company is funded by Santé Ventures (Austin, TX), Prolog Ventures (St. Louis, MO), Fred Goad (Brentwood, TN), 1998 Co-Investing LLC (St. Louis, MO), Vectis Healthcare & Life Sciences Fund II (St. Louis, MO) and Missouri Technology Corporation/IDEA Funds (Jefferson City, MO), along with many other individual investors.